Given the central role of the BCL2-family in the apoptosis machinery, several strategies have been developed to target this network in hematological malignancies, such as synthetic antisense, specific peptides or BH3-mimetics (12, 13). This evidence concerns the gene BCL2 and hematologic disorder.